RT Book, Section
A1 Tano, Zachary E.
A1 Dozier, Jordan
A1 Vaghjiani, Raj G.
A1 Adusumilli, Prasad S.
A2 Sugarbaker, David J.
A2 Bueno, Raphael
A2 Burt, Bryan M.
A2 Groth, Shawn S.
A2 Loor, Gabriel
A2 Wolf, Andrea S.
A2 Williams, Marcia
A2 Adams, Ann
SR Print(0)
ID 1170414092
T1 Immunotherapy for Mesothelioma
T2 Sugarbaker’s Adult Chest Surgery, 3e
YR 2020
FD 2020
PB McGraw-Hill Education
PP New York, NY
SN 9781260026931
LK accesssurgery.mhmedical.com/content.aspx?aid=1170414092
RD 2024/04/19
AB Utilizing  the  body’s  own  immune  responses  to  combat  malignancies  is  not  a  recent  phenomenon.  In  the  late  1880s,  Dr.  William  B.  Coley  utilized  staphylococcal  toxins  following  his  observation  of  tumor  regression  in  patients  who  had  been  exposed  to  infectious  pathogens.1  In  recent  years,  the  application  of  immunotherapy  has  evolved  to  include  many  different  biologic  facets  such  as  modulating  the  tumor  immune  microenvironment  (TME)  and  shifting  its  balance  toward  an  antitumor  state  (Fig.  121-1).  Current  immunotherapeutic  treatments  for  malignant  pleural  mesothelioma  (MPM)  involve  cell-  and  antibody-mediated  immunotherapies.